Summary

Other Scenarios:

Buyer: Genzyme Corporation (GENZ) Last Price: 73.46 Market Cap.: 19.66B
Target: Pharmion Corporation (PHRM) Last Price: 72.32 Market Cap.: 2.71B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
Healthcare 918
Biopharmaceuticals 375
Healthcare Services   150
Medical Devices   254
Outsourced Services   66

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 87)
  • Ad2/HIF-1/VP16
  • Gene Therapy
  • MG Therapeutics Autologous Skeletal Myoblasts
  • Adult Stem Cells
Target (Total: 5)
  • Innohep (Tinzaparin Sodium)
  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
  • Oral Azacitidine
  • Vidaza (Azacitidine)
Buyer
  • Genzyme Genetics
  • Genzyme Diagnostics OSOM hCG Combo
  • Genzyme Diagnostics OSOM Card Pregnancy
  • Genzyme Diagnostics OSOM hCG Urine
Target

n/a

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 13)
  • DRAXIS Health Inc. (USA) (DRAX)
  • etrials Worldwide, Inc. (ETWC)
  • BioMed Realty Trust, Inc. (BMR)
  • Medco Health Solutions Inc. (MHS)
Target (Total: 6)
  • GPC Biotech AG (ADR) (GPCB)
  • Celgene Corporation (CELG)
  • salesforce.com, inc. (CRM)
  • MethylGene Inc. (MYG:CA)
Buyer (Total: 13)
  • Bayer AG (ADR) (BAYRY)
  • Alcon, Inc. (ACL)
  • Schering-Plough Corporation (SGP)
  • Medco Health Solutions Inc. (MHS)
Target (Total: 4)
  • US Oncology, Inc.
  • Cardinal Health, Inc. (CAH)
  • McKesson Corporation (MCK)
  • Government - United Kingdom

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 10,000 513
Revenue Per Employee 415,842.5 558,770.6
Total Revenue 1,036.8 71.5
Total Expenses 926.5 102.6
Other Revenue 5.5 0.0
Cost of Revenue 262.7 19.7
SG&A Expense 308.4 50.0
Research & Development 197.3 30.4
Other Operating Expense 0.0 0.0
Operating Income 110.2 -31.2
Unusual Income 106.4 0.0
LT Debt to Capital 1.69 0
Fwd P/E 20.86 -395.28
Fwd P/Rev 4.24 7.21
Book Value 6,612.9 358.9
Curr Portion of LTD/Cap Lease 696.6 0.0

Individual Company Summary

Focused

Buyer

Focused (): Healthcare > Biopharmaceuticals > Endocrinology/Metabolism > Intermediary Metabolism Disorders

Target

Focused (): Healthcare > Biopharmaceuticals > Oncology

Business Description

Buyer

Genzyme Corporation is a biotechnology company. The Company operates in six units. Renal develops, manufactures and distributes products that treat patients suffering from renal diseases, including chronic renal failure. Therapeutics develops, manufactures and distributes therapeutic products, with a focus on products to treat patients suffering from genetic diseases and other chronic debilitating diseases. Transplant develops, manufactures and distributes therapeutic products that address pre-transplantation, prevention and treatment of graft rejection in organ transplantation and other hematologic and auto-immune disorders. Biosurgery develops, manufactures and distributes biotherapeutics and biomaterial products, with an emphasis on products that meet medical needs in orthopaedics and broader surgical areas. Genetics provides testing services for the oncology, prenatal and reproductive markets. Oncology develops, manufactures and distributes products for the treatment of cancer.

Target

Pharmion Corporation is a global pharmaceutical company that acquires, develops and commercializes products for the treatment of hematology and oncology patients. The Company has established a portfolio of approved products and product candidates focused on the hematology and oncology markets. These include Pharmion?s primary commercial products, Vidaza (azacitidine for injection), which it markets and sells as an approved treatment for myelodysplastic syndromes in the United States, Switzerland, Israel and the Philippines. and Thalidomide Pharmion 50 milligram (Thalidomide Pharmion), a therapy for the treatment of multiple myeloma and certain other forms of cancer, which it sells on a compassionate use or named patient basis in certain countries of Europe. Thalidomide Pharmion is approved in Australia, New Zealand, Turkey, Israel, South Korea and Thailand for the treatment of multiple myeloma. In January 2008, Celgene Corporation has cleared its pending acquisition of Pharmion.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 75.68 72.66
Operating Margin % 17.15 -25.91
Quick Ratio 1.23 3.64
Current Ratio 1.74 4
Coverage Ratio 0.12 -0.15
Total Assets 8,301.7 443.3
Return on Equity % 7.26 -17.79
Return on Assets % 5.78 -14.4
Cash+ ST Inv. Per Share 3.34 6.67
Total Debt 810.4 0.0
Total Debt to Equity % 12.25 0
Total Debt to Tangible Equity % 22.18 0
Debt to Asset % 9.76 0.00

Product Summary

Sector Buyer Target
Healthcare
Biopharmaceuticals
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
  
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Healthcare Services  
Patient Care
The Patient Care Subsector is comprised of companies that provide services to patients for the diagnosis, treatment, and/or prevention of diseases and injuries.
  
Medical Devices  
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
  
Ear/Nose/Throat
The Ear/Nose/Throat Subsector includes medical devices that diagnose and treat conditions affecting these anatomical regions.
  
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
  
Orthopedics
The Orthopedics Subsector includes medical devices that diagnose and treat musculoskeletal diseases involving muscles, bones and joints.
  
Plastic/Reconstructive Surgery
The Plastic/Reconstructive Surgery Subsector includes medical devices that treat and modify a patient's external appearance.
  
Radiology
The Radiology Subsector includes medical devices that generate images of internal physiology.
  
Outsourced Services  
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
  
Drug Delivery Technology
The Drug Delivery Technology Subsector includes companies that develop novel delivery methods for therapeutics.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
Healthcare
Biopharmaceuticals
Cardiovascular System
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Ad2/HIF-1/VP16
  • Gene Therapy
  • MG Therapeutics Autologous Skeletal Myoblasts
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Adult Stem Cells
  
Vascular Disorders  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.

Target Products:

  • Innohep (Tinzaparin Sodium)
  
Thromboembolism  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Target Products:

  • Innohep (Tinzaparin Sodium)
  
Dermatology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Hectorol Capsules (Doxercalciferol)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Genzyme Oncology Clolar (Clofarabine)
  
Digestive System  
Gastrointestinal Tract Disorders  
Intestinal Disorders  
Diarrhea  
Toxin Binding Agents
Therapeutics that treat antibiotic-associated diarrhea by binding to toxins release by C. difficile.

Buyer Products:

  • Tolevamer
  
Endocrinology/Metabolism  
Diabetes  
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes  
Bile Acid Binding Agents
Therapeutics that treat abnormally high blood glucose levels by binding bile acids in the intestine.

Buyer Products:

  • Welchol (Colesevelam Hydrochloride)
  
Intermediary Metabolism Disorders  
Hypercholesterolemia  
Antisense Agents
Therapeutics that treat high cholesterol by targeting specific messenger-RNA and thereby inhibiting the production of specific proteins.

Buyer Products:

  • ISIS 301012 Parenteral (Mipomersen Sodium (ApoB-100 Antisense Inhibitor))
  
Bile Acid Binding Agents
Therapeutics that treat hypercholesterolemia by binding bile acids in the intestine.

Buyer Products:

  • Welchol (Colesevelam Hydrochloride)
  • Colestagel (Colesevelam Hydrochloride)
  
Lysosomal Storage Diseases  
Fabry Disease  
Enzyme Replacement Therapy
Therapeutics that treat Fabry's Disease by providing the missing enzymes that contributes to the disease symptoms.

Buyer Products:

  • Fabrazyme (Agalsidase Beta)
  
Gaucher Disease  
Enzyme Replacement Therapy
Therapeutics that treat Gaucher's Disease by providing the missing enzymes that contributes to the disease symptoms.

Buyer Products:

  • Ceredase (Alglucerase)
  • Cerezyme (Imiglucerase)
  
Hurler Disease  
Enzyme Replacement Therapy
Therapeutics that treat Hurler's Disease by providing the missing enzyme that contributes to the disease symptoms.

Buyer Products:

  • Aldurazyme (Laronidase)
  
Pompe Disease  
Enzyme Replacement Therapy  
Scheie Disease  
Enzyme Replacement Therapy
Therapeutics that treat Scheie's Disease by providing the missing enzyme that contributes to the disease symptoms.

Buyer Products:

  • Aldurazyme (Laronidase)
  
Parathyroid Gland Disorders  
Hyperparathyroidism (HPT)  
Vitamin D Analogs
Therapeutics that act similar to Vitamin D.

Buyer Products:

  • Hectorol Injection (Doxercalciferol)
  • Hectorol Capsules (Doxercalciferol)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Thymoglobulin (Anti-Thymocyte Globulin)
  • Acid Sphingomyelinase Enzyme Replacement Therapy
  • GENZ-112638
  • Thyrogen (Thyrotropin Alfa)
  • Gene Therapy
  • Thyroid Stimulating Hormone (TSH)
  • Genz-642347
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Gene Therapy
  
Hematology
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Genzyme Oncology Clolar (Clofarabine)
  • Desferoxamine (DFO)/Deferitrin (GT56-252)
  • ISIS 301012 Parenteral (Mipomersen Sodium (ApoB-100 Antisense Inhibitor))
  • Thymoglobulin (Anti-Thymocyte Globulin)

Target Products:

  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
  • Oral Azacitidine
Serum Factor Disorders  
Hypercholesterolemia  
Antisense Agents
Therapeutics that treat high cholesterol by targeting specific messenger-RNA and thereby inhibiting the production of specific proteins.

Buyer Products:

  • ISIS 301012 Parenteral (Mipomersen Sodium (ApoB-100 Antisense Inhibitor))
  
Bile Acid Binding Agents
Therapeutics that treat hypercholesterolemia by binding bile acids in the intestine.

Buyer Products:

  • Welchol (Colesevelam Hydrochloride)
  • Colestagel (Colesevelam Hydrochloride)
  
Hyperphosphatemia  
Phosphate Binding Agents
Therapeutics that bind blood phosphorous.

Buyer Products:

  • Renagel (Sevelamer Hydrochloride)
  • Renvela (Sevelamer Carbonate)
  
White Blood Cell (WBC) Disorders  
Myelodysplastic Syndromes (MDS)  
Antimetabolite Agents  
Pyrimidine Analogs
Therapeutics that treat and manage rmyelodysplastic syndrome by interfering with the production of DNA.

Target Products:

  • Vidaza (Azacitidine)
  
Immunology  
Autoimmune Disorders  
Multiple Sclerosis (MS)  
Monoclonal Antibodies
Therapeutics that treat multiple sclerosis by interfering with specific immune pathways implicated in the progression of the disease.

Buyer Products:

  • Genzyme Oncology CAMPATH (Alemtuzumab)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • AMD070 (Chemokine Receptor Inhibitor)
  • Hectorol Capsules (Doxercalciferol)
  • GC-1008
  • FC Receptor 3 Antagonist
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Genzyme Oncology Clolar (Clofarabine)
  • Genzyme Oncology CAMPATH (Alemtuzumab)
  
Infectious Diseases  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • AMD070 (Chemokine Receptor Inhibitor)
  
Musculoskeletal System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Hectorol Capsules (Doxercalciferol)
  
Neurology  
Neuromuscular Disorders  
Multiple Sclerosis (MS)  
Monoclonal Antibodies
Therapeutics that treat multiple sclerosis by interfering with specific immune pathways implicated in the progression of the disease.

Buyer Products:

  • Genzyme Oncology CAMPATH (Alemtuzumab)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Gene Therapy
  • CERE-120 (AAV Neurturin Gene Therapy)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Gene Therapy
  
Oncology
Endocrinology  
Thyroid Gland  
Localized  
Thyroid Stimulating Hormone (TSH)
Therapeutics that treat and manage primary tumors of the thyroid gland by enhancing the uptake of radioiodine which is aimed at ablating cancerous thyroid tissues.

Buyer Products:

  • Thyrogen (Thyrotropin Alfa)
  
Hematology  
Leukemia (White Blood Cell Cancer)  
Lymphoid  
Acute  
Lymphoblastic  
Antimetabolite Agents  
Pyrimidine Analogs  
Chronic  
Lymphocytic (CLL)  
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of leukemia cells and thereby induce their death.

Buyer Products:

  • Genzyme Oncology CAMPATH (Alemtuzumab)
  
Myeloid  
Acute  
Myelogenous (AML)  
Antimetabolite Agents  
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting the production of DNA.

Buyer Products:

  • Genzyme Oncology Clolar (Clofarabine)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • Intravenous Picoplatin (Platinum-Based Compound)
  • Thymoglobulin (Anti-Thymocyte Globulin)
  • Genzyme Oncology Clolar (Clofarabine)
  • Bioenvision Modrenal (Trilostane)
  • Hectorol Capsules (Doxercalciferol)
  • Genzyme Oncology Tasidotin
  • Atiprimod

Target Products:

  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
  • Vidaza (Azacitidine)
  • Oral Azacitidine
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • Genzyme Oncology Topoisomerase I Inhibitors
  • Atiprimod
  • Genzyme Oncology Clolar (Clofarabine)
  • MOZOBIL (Plerixafor)
  
Respiratory System/Thoracic
Lung Cancer
Small Cell Lung Cancer (SCLC)
Alkylating Agents  
Platinum-Based Agents
Therapeutics that treat and manage cancers of the small cells in the lung by interacting with DNA and inhibiting cell division.

Buyer Products:

  • Intravenous Picoplatin (Platinum-Based Compound)
  
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the small cells in the lung by inhibiting a specific enzyme, topoisomerase II, needed for transcription and replication of DNA.

Target Products:

  • Amrubicin (Anthracycline)
  
Ophthalmology  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Gene Therapy
  
Surgery  
Musculoskeletal System  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.

Target Products:

  • Innohep (Tinzaparin Sodium)
  
Transplantation  
Lung  
Rejection Prophylaxis  
Immunoglobulins
Therapeutics that prevent the rejection of lung transplants with target specific proteins.

Buyer Products:

  • Thymoglobulin (Anti-Thymocyte Globulin)
  
Peripheral Blood Progenitor Cell Transplant (PBPCT)  
Preparation  
Stem Cell Mobilizer
Therapeutics used for peripheral blood progenitor cell transplantation by blocking a specific cellular receptor, CXCR4, and triggering the movement of stem cells out of the bone marrow and into circulating blood.

Buyer Products:

  • MOZOBIL (Plerixafor)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the management of rejection and infection in early stages of clinical research where human subject is involved.

Buyer Products:

  • Thymoglobulin (Anti-Thymocyte Globulin)
  
Renal (Kidney)  
Rejection Prophylaxis  
Immunoglobulins
Therapeutics that prevent the rejection of kidney transplants with target specific proteins.

Buyer Products:

  • Thymoglobulin (Anti-Thymocyte Globulin)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the management of rejection and infection associated with transplantation in very early stages of research where no human subject is involved.

Buyer Products:

  • GENZ-29155
  
Urology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • GC-1008
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Small Molecule Compound
  
Urological Disorders  
Kidney (Renal)  
Chronic Renal Failure (CRF)  
Complications  
Hyperparathyroidism  
Vitamin D Analogs
Therapeutics that provide the body with vitamin D like substances that help regulate the levels of calcium and phosphate in the blood.

Buyer Products:

  • Hectorol Injection (Doxercalciferol)
  • Hectorol Capsules (Doxercalciferol)
  
Hyperphosphatemia  
Phosphate Binding Agents
Therapeutics that treat abnormal levels of phosphate in the blood by binding to excess phosphate groups.

Buyer Products:

  • Renvela (Sevelamer Carbonate)
  • Renagel (Sevelamer Hydrochloride)
  
Healthcare Services  
Patient Care  
Ambulatory/Outpatient  
Diagnostic  
Laboratory  
Pathology
Similar to routine clinical lab services, pathology services are provided by licensed medical physicians and therefore may involve the additional role of diagnosis and consultation of results with the referring physician.

Buyer Products:

  • Genzyme Genetics
  
Specialized
Specialized laboratory testing services involving highly specialized equipment, personnel, and procedures.

Buyer Products:

  • Genzyme Genetics
  
Medical Devices  
Clinical Diagnostics  
Chemistry  
Home Testing  
Urine  
Pregnancy
Home pregnancy testing kits.

Buyer Products:

  • Genzyme Diagnostics OSOM hCG Combo
  • Genzyme Diagnostics OSOM Card Pregnancy
  • Genzyme Diagnostics OSOM hCG Urine
  
Point of Care Testing  
Kits  
Infectious Diseases
Test kits used to aid in the diagnosis of infectious diseases.

Buyer Products:

  • Genzyme Diagnostics OSOM BVBLUE
  • Genzyme Diagnostics OSOM Trichomonas Rapid Test
  
Oncology (Cancer)
Test kits used to aid in the diagnosis of cancers.

Buyer Products:

  • Genzyme Diagnostics Hematological Malignancy Tests
  
Reagents  
Calibrators  
Routine Analyte  
Single
Calibrators which contain a specific analyte used to establish the accuracy of chemistry analyzers.

Buyer Products:

  • Genzyme Diagnostics Liquid N-geneous Cholesterol Calibrators
  
Controls  
Routine
Controls used to test the accuracy of discrete chemistry test systems.

Buyer Products:

  • Genzyme Diagnostics N-geneous HDL/LDL Linearity Verifiers
  
Test Kits  
Genetic Analysis  
Cancers  
Leukemia/Lymphoma
Tests designed to determine pre-disposition to leukemia/lymphoma.

Buyer Products:

  • FLT3 Mutation Analysis
  • WT1 RQ-PCR Test
  
Pharmacogenetic
Test kits designed to determine individuals' reaction to specific medications based on their specific genes.

Buyer Products:

  • Invader UGT1A1 Molecular Assay
  • KRAS Mutation Analysis Assay
  • EGFR Mutation Assay
  
Photometric  
Cardiac  
HDL Cholesterol
High density lipoprotein cholesterol.

Buyer Products:

  • Genzyme Diagnostics N-geneous Ultra HDL
  • Genzyme Diagnostics N-geneous Liquid HDL
  
LDL Cholesterol
Low density lipoprotein cholesterol.

Buyer Products:

  • Genzyme Diagnostics N-Geneous LDL
  
Enzymes
Photometric test kits which quantitatively measure for specific metabolic enzymes in body fluids.

Buyer Products:

  • Genzyme Diagnostics Direct Amylase
  • Genzyme Diagnostics Lipase Color
  
Immunoassays  
Reagents  
Test Kits  
Bacterial  
Clostridium Difficile
Immunoassay kits which test for current or previous infection caused by clostridium difficile bacteria.

Buyer Products:

  • Genzyme Diagnostics Clostridium difficile Associated Diarrhea Assay
  
Helicobacter Pylori
Immunoassay kits which test for current or previous infection caused by the helicobacter pylori bacteria.

Buyer Products:

  • Genzyme Diagnostics Helicobacter pylori Diagnostic Product
  
Streptococcus Group A
Immunoassay kits which test for current infection caused by the Streptococcus A bacteria.

Buyer Products:

  • Genzyme Diagnostics OSOM Strep A/Ultra Strep A
  
Mycological (Fungal)  
Candida
Immunoassay kit which tests for current or previous infection caused by the candida yeast.

Buyer Products:

  • Genzyme Diagnostics Candida Assay
  
Parasitic  
Cryptosporidium
Immunoassay kit which tests for the presence of infectious disease or previous infection caused by cryptosporidium.

Buyer Products:

  • Genzyme Diagnostics Giardia/Cryptosporidium Rapid Assay
  
Giardia
Immunoassay kit which tests for the presence of infectious disease or previous infection caused by cryptococcus.

Buyer Products:

  • Genzyme Diagnostics Giardia/Cryptosporidium Rapid Assay
  
Special/Immuno Chemistry  
Endocrine  
Fructosamine
Reagents designed to measure serum fructosamine, an important diabetes test.

Buyer Products:

  • Genzyme Diagnostics GlyPro
  
General Immunodiagnostics  
C Reactive Protein
Immunoassay test kits which test for non specific disease states by testing for C-reactive protein.

Buyer Products:

  • Genzyme Diagnostics N-Geneous Wide Range CRP Reagent/Calibrators
  
Viral  
Epstein Barr Virus
Immunoassay kit which tests for the presence of infectious disease or previous infection caused by the Epstein Barr virus.

Buyer Products:

  • Genzyme Diagnostics OSOM Mono
  
Influenza
Immunoassay kit which tests for the presence of infectious disease caused by Influenza viruses.

Buyer Products:

  • Genzyme Diagnostics OSOM Influenza A & B
  
Ear/Nose/Throat  
Surgical  
Procedure/Region Specific  
Nose/Sinus  
Accessories  
Surgical Sealants
Glue like material used to close up surgery incisions.

Buyer Products:

  • Genzyme Biosurgery Sepragel Sinus
  • Genzyme Biosurgery Seprapack
  
General Surgery  
Invasive  
Procedure/Region Specific  
Hernia Repair  
Grafts/Mesh
Mesh or soft tissue used to repair the opening in an abnormal hernia.

Buyer Products:

  • Genzyme Biosurgery Sepramesh IP
  
Surgical-Site Treatments  
Anti-Adhesives/Anti-Scarring  
Membranes
Membrane-based products applied during interventional procedures to prevent adhesion to medical devices or to prevent scarring of the surgical sites

Buyer Products:

  • Genzyme Biosurgery Seprafilm
  • Genzyme Biosurgery Sepraspray
  
Orthopedics  
Surgical  
Procedure Specific  
Joint Replacement/Reconstruction  
Accessories  
Allografts  
Cartilage
Tissue obtained from cadavers to compensate for excessive tissue removal.

Buyer Products:

  • Genzyme Biosurgery Carticel (Autologous Cultured Chondrocytes)
  • Third Generation Cartilage Repair
  
Treatment  
Pain Management  
Joint/Region Specific  
Ankle/Foot  
Viscosupplementation
Devices used to mimic the synovial fluid in the ankle/shoulder joint in order to relieve pain.

Buyer Products:

  • Genzyme Biosurgery Synvisc
  
Hip  
Viscosupplementation
Devices used to mimic the synovial fluid in the hip joint in order to relieve pain.

Buyer Products:

  • Genzyme Biosurgery Synvisc
  
Knee  
Viscosupplementation
Devices used to mimic the synovial fluid in the knee joint in order to relieve pain associated with osteoarthritis.

Buyer Products:

  • Genzyme Biosurgery Hylastan
  • Third Generation Viscosupplement
  • Genzyme Biosurgery Synvisc-One
  • Genzyme Biosurgery Synvisc
  
Plastic/Reconstructive Surgery  
Surgical  
Procedure/Region Specific  
Skin Grafts  
Artificial Skin  
Acellular
Skin grafts that are do not consist of living human cells.

Buyer Products:

  • Genzyme Biosurgery Hylaform/Hylaform Plus (Hylan B Gel)
  
Cellular
Skin grafts that contain living human cells.

Buyer Products:

  • Genzyme Biosurgery Epicel (Cultured Epidermal Autograft)
  
Treatment  
Wrinkle Removal  
Hyaluronic Acid  
Radiology  
Nuclear  
Gamma Camera  
Contrast Agents  
Radionuclides  
Adjuncts
Radioactive materials that are introduced to the body for nuclear imaging purposes.

Buyer Products:

  • Thyrogen (Thyrotropin Alfa)
  
Outsourced Services  
Development/Manufacturing Services  
Contract Manufacturing Organizations (CMO)  
Medical Devices
Contract Manufacturing Organizations that manufacture (and/or design, develop) medical devices and products for other organizations.

Buyer Products:

  • Genzyme Advanced Biomaterials
  • Genzyme Diagnostics Clinical Chemistry Reagents/Raw Materials
  • Genzyme Biosurgery Synvisc
  
Pharmaceuticals  
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.

Buyer Products:

  • Genzyme Pharmaceuticals
  
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.

Buyer Products:

  • Genzyme Pharmaceuticals
  
Drug Delivery Technology  
Oral Delivery  
Lipid Based
Drug Delivery Technologies used to deliver drugs in a liposomal/lipid formulation.

Buyer Products:

  • Genzyme Pharmaceuticals Lipobridge
  • Genzyme Pharmaceuticals LipoMask
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Pfizer Inc. n/a 144,347.120 17.73 9.11 2.98 3.03 6.24
sanofi-aventis (ADR) n/a 98,531.811 16.69 9.14 2.25 2.40 n/a
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
Vion Pharmaceuticals, Inc. n/a 25.897 0.00 -0.71 1,194.74 n/a 3.14
Buyer
  Johnson & Johnson n/a 174,233.403 16.47 14.11 2.85 2.79 11.97
Roche Holding Ltd. (ADR) n/a 162,161.754 18.24 19.03 3.86 3.93 5.53
Pfizer Inc. n/a 144,347.120 17.73 9.11 2.98 3.03 6.24
Novartis AG (ADR) n/a 108,444.656 9.08 13.48 2.78 2.71 3.88
sanofi-aventis (ADR) n/a 98,531.811 16.69 9.14 2.25 2.40 n/a
Abbott Laboratories n/a 78,894.465 21.88 16.18 3.04 2.85 40.89
Amgen, Inc. n/a 48,051.405 15.18 10.82 3.25 3.28 14.57
Teva Pharmaceutical Industries Ltd (ADR) n/a 38,602.146 19.78 17.88 4.10 3.61 11.36
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
Smith & Nephew plc (ADR) n/a 11,640.029 33.45 25.30 3.67 3.49 41.40
Target
  Pfizer Inc. n/a 144,347.120 17.73 9.11 2.98 3.03 6.24
GlaxoSmithKline plc (ADR) n/a 115,986.006 11.18 10.85 2.57 2.53 15.20
sanofi-aventis (ADR) n/a 98,531.811 16.69 9.14 2.25 2.40 n/a
Genentech, Inc. n/a 83,607.511 30.19 25.16 7.13 6.43 9.13
Eli Lilly & Co. n/a 56,508.154 19.14 12.64 3.03 2.79 5.04
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
Eisai Co., Ltd (ADR) n/a 9,661.528 13.56 13.89 1.46 1.40 2.29
Millennium Pharmaceuticals, Inc. n/a 4,249.041 284.76 58.61 8.05 7.65 5.90
SuperGen, Inc. n/a 135.648 10.37 -12.63 5.91 3.71 1.48
Poniard Pharmaceuticals, Inc. n/a 132.393 0.00 -3.07 n/a 12.14 1.53
Vion Pharmaceuticals, Inc. n/a 25.897 0.00 -0.71 1,194.74 n/a 3.14

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  DRAXIS Health Inc. (USA) 23.00% 170.353 102.74 21.72 2.16 1.77 1.55
etrials Worldwide, Inc. 10.50% 25.417 0.00 -5.12 1.13 n/a 1.30
BioMed Realty Trust, Inc. 8.40% 1,418.770 25.49 11.09 5.33 4.95 1.03
Medco Health Solutions Inc. n/a 21,920.926 24.04 18.60 0.49 0.45 n/a
Forest City Enterprises, Inc. n/a 3,679.190 33.31 n/a 2.97 n/a 3.68
Open Text Corporation (USA) n/a 1,521.839 49.79 16.75 2.25 2.23 n/a
Phase Forward Incorporated n/a 691.529 23.68 42.63 5.15 4.13 3.69
XOMA Limited n/a 337.556 0.00 -17.00 4.30 4.08 36.49
Dyax Corp. n/a 276.699 0.00 -6.03 10.60 5.83 9.69
QAD Inc. n/a 266.676 61.64 49.59 1.05 1.01 6.45
Genetic Technologies Limited (ADR) n/a 46.024 0.00 n/a 3.94 n/a 4.15
Pharsight Corporation n/a 44.598 0.00 29.56 1.59 1.58 5.07
Insightful Corporation n/a 13.590 0.00 n/a 0.61 n/a 1.35
Target
  GPC Biotech AG (ADR) 66.00% 123.561 0.00 -1.04 3.95 3.84 1.63
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
salesforce.com, inc. n/a 6,759.538 368.29 174.97 9.03 6.62 16.14
MethylGene Inc. n/a 87.304 0.00 n/a 6.00 n/a 1.75
Ben Venue Laboratories, Inc. n/a n/a n/a n/a n/a n/a n/a
Ash Stevens, Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Bayer AG (ADR) n/a 54,726.881 7.55 14.14 1.19 1.27 n/a
Alcon, Inc. n/a 40,206.352 25.34 21.89 7.18 6.56 15.12
Schering-Plough Corporation n/a 32,021.742 0.00 13.35 2.52 1.78 72.12
Medco Health Solutions Inc. n/a 21,920.926 24.04 18.60 0.49 0.45 n/a
Kirin Holdings Company, Ltd. (ADR) n/a 16,526.365 35.67 30.52 1.08 0.97 2.66
Edwards Lifesciences Corp n/a 2,463.176 21.80 18.32 2.26 2.07 6.80
Abaxis, Inc. n/a 581.513 48.57 47.64 6.02 5.88 5.82
Discovery Laboratories, Inc. n/a 171.449 0.00 -3.38 n/a 67.75 4.42
DRAXIS Health Inc. (USA) n/a 170.353 102.74 21.72 2.16 1.77 1.55
Poniard Pharmaceuticals, Inc. n/a 132.393 0.00 -3.07 n/a 12.14 1.53
GTC Biotherapeutics, Inc. n/a 49.147 0.00 n/a 3.60 3.11 61.48
Dechra Pharmaceuticals PLC n/a n/a n/a n/a n/a n/a n/a
Chugai Pharmaceutical Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
Target
  US Oncology, Inc. 19.00% n/a n/a n/a n/a n/a n/a
Cardinal Health, Inc. 11.00% 19,851.610 12.83 14.65 0.22 0.21 15.33
McKesson Corporation 9.00% 16,575.105 17.63 17.42 0.17 0.16 5.60
Government - United Kingdom n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Roche Holding Ltd. (ADR) n/a 162,161.754 18.24 19.03 3.86 3.93 5.53
Wyeth n/a 55,284.879 11.98 12.11 2.47 2.48 4.04
Bayer AG (ADR) n/a 54,726.881 7.55 14.14 1.19 1.27 n/a
AstraZeneca plc (ADR) n/a 54,545.064 9.47 8.41 1.91 1.77 n/a
Medtronic, Inc. n/a 53,456.085 23.97 18.96 4.13 4.07 45.34
Alcon, Inc. n/a 40,206.352 25.34 21.89 7.18 6.56 15.12
Schering-Plough Corporation n/a 32,021.742 0.00 13.35 2.52 1.78 72.12
Medco Health Solutions Inc. n/a 21,920.926 24.04 18.60 0.49 0.45 n/a
Allergan, Inc. n/a 16,937.756 33.92 21.77 4.30 3.80 77.06
Kirin Holdings Company, Ltd. (ADR) n/a 16,526.365 35.67 30.52 1.08 0.97 2.66
Shire plc (ADR) n/a 11,013.064 0.00 19.66 4.52 3.82 n/a
C.R. Bard, Inc. n/a 9,315.937 22.92 21.39 4.23 3.86 8.67
Hospira, Inc. n/a 6,679.270 48.84 17.23 1.94 1.85 n/a
Target
  Pfizer Inc. n/a 144,347.120 17.73 9.11 2.98 3.03 6.24
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
Cardinal Health, Inc. n/a 19,851.610 12.83 14.65 0.22 0.21 15.33
McKesson Corporation n/a 16,575.105 17.63 17.42 0.17 0.16 5.60
GPC Biotech AG (ADR) n/a 123.561 0.00 -1.04 3.95 3.84 1.63
MethylGene Inc. n/a 87.304 0.00 n/a 6.00 n/a 1.75
US Oncology, Inc. n/a n/a n/a n/a n/a n/a n/a
LEO Pharma A/S n/a n/a n/a n/a n/a n/a n/a
Ash Stevens, Inc. n/a n/a n/a n/a n/a n/a n/a
Dainippon Sumitomo Pharma Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
Ben Venue Laboratories, Inc. n/a n/a n/a n/a n/a n/a n/a
Nippon Shinyaku Co., Ltd. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 3,784.1 267.3 4,051.4
Other Revenue 29.4 0.0 29.4
Total Revenue 3,813.5 267.3 4,080.8
Cost of Revenue 927.3 73.1 1,000.4
SG&A Expense 1,187.2 143.2 1,330.4
Depreciation & Amortization 201.1 9.9 211.0
Research & Development 737.7 102.4 840.1
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 0.0 0.0
Unusual Expense (Income) 106.4 8.0 114.4
Total Expenses 3,159.7 336.5 3,496.2
Operating Income 653.9 -69.2 584.6
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 78.5 10.2 88.7
Other, Net 3.3 0.0 3.3
Income Before Taxes 735.7 -59.1 676.6
Income Taxes 255.5 4.8 260.3
Income After Taxes 480.2 -63.9 416.3
Net Income - Excl. Xord. Items 480.2 -63.9 416.3
Net Income - Incl. Xord. Items 480.2 -63.9 416.3
Income Avail. to Common 480.2 -63.9 416.3
Share Items
Basic Avg. Shares Outstanding 265.4 37.3 302.7
Basic EPS - Excl. Xord. Items 1.81 n/a 1.38
Basic EPS - Incl. Xord. Items 1.81 n/a 1.38
Full Dilution Adjustment 1.9 0.0 1.9
Fully Diluted Shares Outstanding 283.4 37.3 320.7
F.D. EPS - Excl. Xord. Items 1.69 n/a 1.30
F.D. EPS - Incl. Xord. Items 1.69 n/a 1.30
Balance Sheet
Assets
Cash and Equivalents 867.0 178.9 1,045.9
ST Investments 80.4 69.7 150.1
Accounts Receivable 904.1 45.0 949.1
Inventory 439.1 12.8 452.0
Prepayments and Advances 154.2 2.8 157.0
Other Current Assets 164.3 13.6 177.9
Current Assets 2,609.2 322.8 2,932.0
Accum D&A 0.0 0.0 0.0
PPE, Net 1,968.4 11.4 1,979.8
Goodwill & Intangibles 2,959.5 103.1 3,062.6
Long Term Investments 602.1 0.0 602.1
Other Assets 0.0 0.0 0.0
Other LT Assets 162.5 6.0 168.5
Total Assets 8,301.7 443.3 8,745.1
Liabilities
Accounts Payable 128.4 14.3 142.7
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 645.6 66.3 712.0
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 696.6 0.0 696.6
Other (Current) Liabilities 31.8 0.0 31.8
Current Liab. 1,502.4 80.6 1,583.0
LT Debt 113.7 0.0 113.7
Total LT Debt 113.7 0.0 113.7
Deferred Taxes 0.0 2.7 2.7
Other LT Liab. 72.6 1.1 73.7
Total Liabilities 1,688.8 84.4 1,773.2
Shareholders Equity
Common Stock 2.7 0.0 2.7
Additional Paid in Capital 5,369.5 631.7 6,001.2
Retained Earnings 826.7 -290.7 536.0
Other Equity 414.1 17.9 431.9
Total Equity 6,612.9 358.9 6,971.9
Total Liab. & Equity 8,301.7 443.3 8,745.1
Shares Outstanding 266.0 37.4 303.4
Cash Flow
Operating Cash Flow
CF Net Income 480.2 -63.9 416.3
CF Depreciation 338.2 12.6 350.8
CF Deferred Taxes -106.1 0.0 -106.1
Other Non-Cash Items 324.3 3.2 327.5
Change in Working Capital -117.9 24.5 -93.3
Total Cash From Operating Activities 918.7 -23.5 895.1
Investing Cash Flow (not calculated)
Capital Expenditures -473.2 -6.7 -480.0
Other Investing Cash Flows -117.8 8.6 -109.3
Total Cash From Investing Activities -591.1 1.8 -589.2
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock 54.2 138.0 192.2
Purchase and Retirement of Debt -5.9 -0.9 -6.8
Other Financing Cash Flow 16.3 0.4 16.7
Total Cash From Financing Activities 64.6 137.5 202.1
Exchange Rate Effects -17.4 3.2 -14.2
Net Change in Cash 374.8 119.0 493.8
Cash Taxes Paid 447.6 3.0 450.5
Cash Interest Paid 5.5 0.2 5.7